###begin article-title 0
###xml 114 115 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 14 19 <span type="species:ncbi:9606">Human</span>
###xml 129 134 <span type="species:ncbi:9606">Human</span>
Survey of the Human Pancreatic beta-Cell G1/S Proteome Reveals a Potential Therapeutic Role for Cdk-6 and Cyclin D1 in Enhancing Human beta-Cell Replication and Function In Vivo
###end article-title 0
###begin p 1
N.F.-T. and T.A.B. contributed equally to this article.
###end p 1
###begin title 2
OBJECTIVES
###end title 2
###begin p 3
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 140 146 <span type="species:ncbi:10090">murine</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 261 266 <span type="species:ncbi:9606">human</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
To comprehensively inventory the proteins that control the G1/S cell cycle checkpoint in the human islet and compare them with those in the murine islet, to determine whether these might therapeutically enhance human beta-cell replication, to determine whether human beta-cell replication can be demonstrated in an in vivo model, and to enhance human beta-cell function in vivo.
###end p 3
###begin title 4
RESEARCH DESIGN AND METHODS
###end title 4
###begin p 5
###xml 129 130 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 151 156 <span type="species:ncbi:9606">human</span>
Thirty-four G1/S regulatory proteins were examined in human islets. Effects of adenoviruses expressing cdk-6, cdk-4, and cyclin D1 on proliferation in human beta-cells were studied in both invitro and in vivo models.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin p 7
###xml 182 183 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 367 368 364 365 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 29 35 <span type="species:ncbi:10090">murine</span>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 150 156 <span type="species:ncbi:10090">murine</span>
###xml 320 325 <span type="species:ncbi:9606">Human</span>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 448 453 <span type="species:ncbi:9606">human</span>
Multiple differences between murine and human islets occur, most strikingly the presence of cdk-6 in human beta-cells versus its low abundance in the murine islet. Cdk-6 and cyclin D1 in vitro led to marked activation of retinoblastoma protein phosphorylation and cell cycle progression with no induction of cell death. Human islets transduced with cdk-6 and cyclin D1 were transplanted into diabetic NOD-SCID mice and markedly outperformed native human islets in vivo, maintaining glucose control for the entire 6 weeks of the study.
###end p 7
###begin title 8
CONCLUSIONS
###end title 8
###begin p 9
###xml 212 213 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 57 62 <span type="species:ncbi:9606">Human</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
The human G1/S proteome is described for the first time. Human islets are unlike their rodent counterparts in that they contain easily measurable cdk-6. Cdk-6 overexpression, alone or in combination with cyclin D1, strikingly stimulates human beta-cell replication, both in vitro as well as in vivo, without inducing cell death or loss of function. Using this model, human beta-cell replication can be induced and studied in vivo.
###end p 9
###begin p 10
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 235 236 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 236 236 230 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4"/>
###xml 237 238 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 380 381 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 381 381 372 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7"/>
###xml 381 381 372 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8"/>
###xml 381 381 372 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9"/>
###xml 381 381 372 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10"/>
###xml 381 381 372 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11"/>
###xml 381 381 372 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12"/>
###xml 382 384 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 481 483 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 483 483 471 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15"/>
###xml 484 486 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 921 923 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24"/>
###xml 923 923 905 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25"/>
###xml 924 926 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
Recent reports demonstrate that human islet transplantation is technically feasible (1,2), that replication is a major means of maintaining beta-cell numbers in rodents, and that all rodent adult beta-cells are capable of replicating (3-5). In addition, advances in understanding the signaling pathways and growth factors that can induce beta-cell replication continue to accrue (6-13). It is now clear that both type 1 and type 2 diabetes result from a decline in beta-cell mass (14-16). Collectively, these observations underscore a need to understand, and to therapeutically exploit the molecular mechanisms underlying beta-cell replication and regeneration. Abundant data in mice have demonstrated that the "G1/S checkpoint," or the "G1/S pathway" (supplemental Fig. 1, available in an online appendix at ), in the cell cycle is critical in regulating rodent beta-cell replication and physiological function (rev. in 17-26).
###end p 10
###begin p 11
###xml 166 168 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 169 171 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 172 174 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 483 484 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 484 484 472 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4"/>
###xml 484 484 472 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5"/>
###xml 485 486 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 487 488 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 488 488 476 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10"/>
###xml 488 488 476 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11"/>
###xml 488 488 476 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12"/>
###xml 489 491 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 492 494 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 494 494 482 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18"/>
###xml 495 497 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 498 500 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 501 503 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 768 770 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 771 773 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 774 776 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 776 776 758 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30"/>
###xml 777 779 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 316 321 <span type="species:ncbi:9606">human</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
###xml 687 692 <span type="species:ncbi:9606">human</span>
In contrast to this richness in knowledge regarding beta-cell cycle control in the mouse, relatively little is known regarding cell cycle control in the human islet (17,23,26). This is important because the fundamental reason for studying beta-cell replication is to leverage such knowledge for expanding functional human beta-cell mass for the treatment or prevention of diabetes. Significantly, whereas abundant examples exist for robust induction of rodent beta-cell replication (3-6,9-13,17-19,27,28), multiple reports suggest that in contrast to rodents, human beta-cell replication is a rare event; indeed, several authors have reported that they cannot demonstrate replication in human beta-cells either under basal conditions or in response to growth factors (15,17,29-31).
###end p 11
###begin p 12
###xml 354 355 348 349 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 525 526 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 178 184 <span type="species:ncbi:10090">murine</span>
###xml 262 268 <span type="species:ncbi:10090">murine</span>
###xml 298 303 <span type="species:ncbi:9606">human</span>
###xml 421 426 <span type="species:ncbi:9606">human</span>
###xml 541 546 <span type="species:ncbi:9606">human</span>
###xml 601 606 <span type="species:ncbi:9606">human</span>
We therefore sought to catalog in the human islet the molecules that control the G1/S checkpoint of the cell cycle. We report such a G1/S roadmap and compare it with that of the murine islet. We demonstrate that whereas cdk-6 is difficult to detect or absent in murine beta-cells, it is present in human beta-cells. Furthermore, we show that cdk-6 and a d-cyclin partner can be used to markedly accelerate replication in human beta-cells in vitro. Most importantly, we show that combined overexpression of cdk-6 with cyclin D1 also leads to human beta-cell replication in vivo and results in enhanced human islet engraftment and function in an in vivo transplant diabetes model.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin title 14
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human islets.
###end title 14
###begin p 15
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 397 402 <span type="species:ncbi:9606">human</span>
Human islets were obtained through the National Institutes of Health- and Juvenile Diabetes Research Foundation-supported Islet Cell Resource Consortium (). On arrival, human islets were washed with PBS and incubated in RPMI medium (Gibco, Grand Isle, NY) containing 5.5 mmol/l glucose, 1% penicillin, and streptomycin with 10% FBS until they were used for experiments. Receipt of, and work with, human islets was approved in advance by the University of Pittsburgh Institutional Review Board.
###end p 15
###begin title 16
Immunoblotting and RT-PCR.
###end title 16
###begin p 17
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 677 684 677 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figs. 1</xref>
###xml 684 684 684 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2"/>
###xml 684 684 684 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3"/>
###xml 684 684 684 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4"/>
###xml 684 684 684 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5"/>
###xml 684 684 684 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6"/>
###xml 684 684 684 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7"/>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">8</xref>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 808 814 808 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human and animal islet extracts were prepared within 24-48 h of arrival using nuclear extract buffer resolved using 7.5-15% SDS-PAGE depending on the molecular weight of the protein in question and then transferred to Immobilon-P membranes (Millipore, Bradford, MA) as we have described previously (23,24). Primary antisera and dilutions used are shown in supplemental Table 1 (available in the online appendix). Each immunoblot was performed a minimum of three times on a minimum of three different islet preparations, each accompanied by an appropriate housekeeping protein control, either tubulin or actin. Representative immunoblots and actin/tubulin controls are shown in Figs. 1-8. RT-PCR for cdk-4 and cdk-6 were preformed as described previously (9,13,22,23) using primers described in the legend to Fig. 1.
###end p 17
###begin title 18
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human beta-cell proliferation, cell death, and glucose-stimulated insulin secretion in vitro.
###end title 18
###begin p 19
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human islet cell proliferation was assayed as reported previously (23) with the exception that the islets were labeled with bromodeoxyuridine (BrdU) for the final 24 h using a 1:1,000 dilution of BrdU (Sigma) and stained for BrdU and insulin as described subsequently for in vivo staining. Propidium iodide was used for nuclear staining and visualization of pyknotic nuclei. Glucose-stimulated insulin secretion was performed as described previously (23).
###end p 19
###begin title 20
###xml 31 36 <span type="species:ncbi:9606">human</span>
Quantification of transplanted human beta-cell proliferation in vivo.
###end title 20
###begin p 21
###xml 86 87 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 88 90 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 90 90 87 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24"/>
###xml 91 93 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 94 96 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
beta-Cell proliferation was assessed in vivo in renal grafts as described previously (9,23-25,32) with the following modifications. Graft-containing kidneys were harvested on the third day after transplantation, 6 h after BrdU injection, fixed in 4% paraformaldehyde overnight at 4degreesC, paraffin-embedded, and sectioned. In the graft-containing kidneys, three serial sections separated by 25 mum were deparaffinized, rehydrated, and treated in prewarmed 1M HCl for 1 h at 37degreesC, blocked in 2% BSA/PBS for 1 h, then incubated overnight with anti-BrdU (Abcam, Cambridge, MA) and anti-insulin antibodies (Zymed, San Francisco, CA). After serial washing in PBST, slides were incubated for 1 h with secondary antibodies, gel-mounted, and coverslipped. Two sections per graft were analyzed. Three fields per section were quantified for BrdU- and insulin-positive cells.
###end p 21
###begin title 22
Immunocytochemistry and laser confocal microscopy.
###end title 22
###begin p 23
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 235 241 <span type="species:ncbi:9913">bovine</span>
For cdk-6 immunohistochemistry, human islets were fixed in 2% paraformaldehyde for 12 min at room temperature followed by three 5-min washes in PBS. Islets were then blocked in 1x PBS, 0.2% Triton-X-100, 0.1 mmol/l CaCl, with 2% fetal bovine serum for 1 h at room temperature. Primary antibodies (supplemental Table 1, available in the online appendix) were used at 20degreesC overnight. Secondary antibodies were incubated for 1 h at room temperature. After three 5-min washes in PBS, islets were placed on microscope slides, coverslipped in antifade gel mount, and stored in the dark at 20degreesC. Islets were imaged using an Olympus Fluoview 1000 laser confocal microscope.
###end p 23
###begin title 24
Adenoviruses.
###end title 24
###begin p 25
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 180 182 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 246 248 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 312 314 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 140 143 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 207 212 <span type="species:ncbi:9606">human</span>
Adenoviruses expressing human cyclin D1, human cdk-4 (Ad.hcdk-4), beta galactosidase (Ad.lacZ), and green fluorescent protein driven by the CMV promoter were described previously (23). Adenovirus expressing human cdk-6 was prepared as described (23). Multiplicity of infection (MOI) were defined as in the past (23), and duration of exposure used is detailed in the figure legends.
###end p 25
###begin title 26
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Human islet marginal mass model in NOD-SCID mice.
###end title 26
###begin p 27
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 503 504 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 505 507 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 508 510 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 511 513 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 230 235 <span type="species:ncbi:9606">human</span>
Human islets were transplanted under the renal capsule of streptozotocin-induced diabetic NOD-SCID mice as described in detail previously (6,9,32,33). One islet equivalent (IEQ) was defined as 125 mum. All transplant studies with human islets in the streptozotocin-induced diabetes model were approved by, and performed in accordance with, the University of Pittsburgh Institutional Animal Care and Use Committee. Intraperitoneal glucose tolerance tests (IPGTTs) were performed as described previously (9,13,24,25).
###end p 27
###begin p 28
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
For the BrdU and propidium iodide experiments, Student's unpaired two-tailed t-test was used. For the marginal mass NOD-SCID transplant model, one-way ANOVA for repeated measures was performed. P values <0.05 were considered significant.
###end p 28
###begin title 29
RESULTS
###end title 29
###begin p 30
###xml 120 126 120 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 267 273 267 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 273 274 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 596 604 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 604 605 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 208 213 <span type="species:ncbi:9606">human</span>
###xml 380 385 <span type="species:ncbi:9606">human</span>
###xml 624 629 <span type="species:ncbi:9606">human</span>
The results of a screen for each of the G1/S regulatory molecules using protein extracts from human islets are shown in Fig. 1. In each of the panels, results are shown for two different, but representative, human islet extracts, labeled H1 and H2. As can be seen in Fig. 1A, each of the three members of the so-called "pocket protein family," pRb, p107, and p130, are present in human islets. The pocket proteins regulate cell cycle progression by binding to the E2F family of transcription factors, which in turn regulate the expression of the myriad genes required for cell cycle progression. Figure 1B demonstrates that human islets contain E2Fs 1, 3, 4, and 7 but not E2Fs 2, 5, and 6.
###end p 30
###begin p 31
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 523 524 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 543 544 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 688 690 688 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H:</italic>
###xml 1341 1343 1341 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I:</italic>
###xml 1432 1433 1432 1433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 627 632 <span type="species:ncbi:9606">human</span>
###xml 644 650 <span type="species:ncbi:10090">murine</span>
###xml 821 826 <span type="species:ncbi:9606">human</span>
###xml 1327 1332 <span type="species:ncbi:9606">human</span>
###xml 1374 1379 <span type="species:ncbi:9606">human</span>
###xml 1472 1477 <span type="species:ncbi:9606">Human</span>
###xml 1513 1518 <span type="species:ncbi:9606">human</span>
###xml 1630 1635 <span type="species:ncbi:9606">human</span>
Immunoblots for the G1/S control molecules in the human islet. Each panel represents two examples of immunoblots of human islet extracts, and each is representative of at least three, and as many as eight, human islet preparations. Islets were extracted between 24 and 48 h of arrival. Antisera are shown in supplemental Table 1 of the online appendix. A: The pocket proteins. B: E2F family. C: Cyclin family. D: cdk family (cdk-4 and cdk-4' represents immunoblots preformed with Abcam and sc-260G antisera as explained in H). E: INK4 family. F: KIP/CIP/WAF family. G: Miscellaneous other G1/S molecules (note that HDM2 is the human homolog of murine MDM2, the ubiquitin ligase for p53). H: Results obtained with multiple cdk-4 and cdk-6 antisera. To define the specificity of several available cdk-4 and cdk-6 antisera, human islets were transduced with adenoviruses (250 MOI) encoding cdk-1, cdk-2, cdk-4, and cdk-6 for 1 h, incubated for 48 h, and then extracted, resolved on SDS-PAGE, and immunoblotted for the six antisera shown. As can be seen, none of the cdk-4 or cdk-6 antisera cross-reacted with cdk-1, cdk-2, cdk-4, or cdk-6, and each was upregulated by the cognate cdk. All three cdk-6 antisera recognized cdk-6 in normal nontransduced islets, but only the sc-260 cdk-4 antiserum was able to detect cdk-4 in normal human islets. I: RT-PCR for cdk-4 and cdk-6 in human islets. MR indicates molecular weight markers, and H2O indicates a lane with no polymerase. Human osteosarcoma cells (SaOS2) and the human kidney cell line HK2 are positive controls. Sequencing of the amplified PCR products confirmed the presence of human cdk-4 and cdk-6. The primers used spanned intron-exon boundaries and generated products of the expected size: 484 bp for cdk-4 (vs. 754 for the genomic product) and 341 bp (vs. 8,457 for the genomic product). The primers used were: cdk-6 5'-GGCGCCTATGGGAAGGTGTTC-3'; 5'-AAAGTCCAGACCTCGGAGAAGC-3'; cdk-4 5'-GTGGCTGAAATTGGTGTCGG-3'; 5'-GCCATCTGGTAGCTGTAGATTC-3'.
###end p 31
###begin p 32
###xml 100 109 100 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figures 1</xref>
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 287 292 <span type="species:ncbi:9606">human</span>
The pocket proteins are phosphorylated by two kinase complexes, the cdks and their cyclin partners. Figures 1C and D demonstrate that human islets contain all three D cyclins, and easily measurable cyclin E, with less abundant, or at least less easily detectable, cyclin A. In addition, human islets contain easily demonstrable cdk1 (also called cdc2) and cdk2, the cognate partners of cyclins A and E.
###end p 32
###begin p 33
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 267 273 267 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 273 274 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 607 613 607 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 613 614 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 1390 1396 1390 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 1396 1397 1396 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
###xml 847 852 <span type="species:ncbi:9606">human</span>
###xml 1172 1177 <span type="species:ncbi:9606">human</span>
###xml 1345 1350 <span type="species:ncbi:9606">human</span>
###xml 1376 1381 <span type="species:ncbi:9606">human</span>
We had preliminarily reported that human islets lack cdk-4 based on studies using antisera from Abcam and Santa Cruz and appropriate positive and negative controls (34). However, we were able to observe cdk-4 immunoreactivity using a third cdk-4 antiserum (cdk-4' in Fig. 1D). To be certain that the cdk-4 immunoblots accurately reflected endogenous cdk-4 and not cross-reactivity with another cdk or other protein, we adenovirally overexpressed human cdk-1, cdk-2, cdk-4, and cdk-6 in human islets and performed immunoblotting using three different commercially available cdk-4 antisera. As can be seen in Fig. 1H, the Abcam 3112 and Santa Cruz 749 antisera failed to detect cdk-4 in human islets, although cdk-4 immunoreactivity was readily visible by both antisera when cdk-4 was overexpressed. In contrast, cdk-4 was easily observed in normal human islet preparations under basal conditions using the Santa Cruz 260G antiserum, and this was enhanced by overexpression of cdk-4 but not by overexpression of cdk-1, cdk-2, or cdk-6. These observations suggest that the three cdk-4 antisera do not cross-react with other cdks and that authentic cdk-4 is indeed present in human islets, but at sufficiently low levels that it is only observable using the third cdk-4 antiserum. RT-PCR and sequencing of the amplified cDNA products confirmed that human cdk-4 mRNA in present in human islets (Fig. 1I).
###end p 33
###begin p 34
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 122 128 122 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 304 310 304 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 310 311 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</italic>
###xml 795 801 795 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 801 802 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 47 53 <span type="species:ncbi:10090">murine</span>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 215 220 <span type="species:ncbi:9606">human</span>
###xml 377 382 <span type="species:ncbi:9606">human</span>
###xml 750 755 <span type="species:ncbi:9606">human</span>
###xml 781 786 <span type="species:ncbi:9606">human</span>
Surprisingly, in marked contrast to results in murine islets (17,23,35,36), human islets contain the cdk-4 homolog cdk-6 (Fig. 1D). To confirm that the cdk-6 immunoblot accurately reflected the presence of cdk-6 in human islets, we performed immunoblots using three different cdk-6 antisera, as shown in Fig. 1H. As can be seen in the figure, cdk-6 was observed in each of the human islet preparations with each of the three antisera used, and in each case, there was a specific increase in expression after transduction with Ad.cdk-6. Moreover, cdk-6 immunoreactivity was not enhanced by overexpression of cdk-1, cdk-2, nor cdk-4, indicating specificity of the antisera for cdk-6. RT-PCR and sequencing of the amplified cDNA products confirmed that human cdk-6 mRNA is present in human islets (Fig. 1I).
###end p 34
###begin p 35
###xml 138 145 138 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figs. 1</xref>
###xml 145 146 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 273 279 273 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 250 255 <span type="species:ncbi:9606">human</span>
Upstream of the cdks and cyclins are two families of cell cycle inhibitors, the INK4 family and the CIP/KIP/WAF family. As can be seen in Figs. 1E and F, each of the four INK4s and each of the three CIP/KIP/WAF family members is easily detectable in human islets. Finally, Fig. 1G shows a number of additional G1/S regulatory molecules that are involved in cell cycle control.
###end p 35
###begin p 36
###xml 198 204 195 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 204 205 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 587 593 584 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 593 594 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 919 925 910 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 925 926 916 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 268 271 <span type="species:ncbi:10116">rat</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
###xml 387 390 <span type="species:ncbi:10116">rat</span>
###xml 443 446 <span type="species:ncbi:10116">rat</span>
###xml 487 492 <span type="species:ncbi:9606">human</span>
###xml 628 633 <span type="species:ncbi:9606">human</span>
###xml 901 906 <span type="species:ncbi:9606">human</span>
To independently confirm the mentioned immunoblot studies, and to determine whether cdk-6 was present specifically in human beta-cells, we performed immunohistochemistry for cdk-6. The upper row of Fig. 2A demonstrates that cdk-6 is absent or at least undetectable in rat islets. The middle row of this figure is a positive control and demonstrates that when human cdk-6 is expressed in rat islets using Ad.cdk-6, it is now easily observed in rat islets. These findings demonstrate that human cdk-6 can be reliably assessed using these immunohistochemistry techniques. The bottom row of Fig. 2A shows that native, nontransduced human islets contain easily measurable cdk-6 and that cdk-6 is present in the cytosol in beta-cells. Interestingly, cdk-6 appears almost exclusively in the cytoplasmic compartment and is absent from the nucleus. These results are confirmed by higher-power magnification of human beta-cells (Fig. 2B).
###end p 36
###begin p 37
###xml 65 67 65 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</italic>
###xml 75 86 75 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 243 255 243 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">middle panel</italic>
###xml 375 386 375 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 510 512 510 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</italic>
###xml 43 46 <span type="species:ncbi:10116">rat</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 111 114 <span type="species:ncbi:10116">rat</span>
###xml 224 227 <span type="species:ncbi:10116">rat</span>
###xml 262 265 <span type="species:ncbi:10116">rat</span>
###xml 393 398 <span type="species:ncbi:9606">human</span>
###xml 597 602 <span type="species:ncbi:9606">human</span>
Confocal immunohistochemistry for cdk-6 in rat and human islets. A: In the upper panel, as a negative control, rat islets that do not contain cdk-6 were stained for insulin (red) or cdk-6 (green). Cdk-6 is not detectable in rat islets. In the middle panel, when rat islets are transduced with Ad.cdk-6 as a positive control, cdk-6 immunoreactivity is easily observed. In the lower panel, when human islets are stained for cdk-6, immunoreactivity is easily observed and colocalizes with insulin-positive cells. B: A higher-power magnification demonstrates that cdk-6 is present in the cytoplasm of human beta-cells. (A high-quality digital representation of this figure is available in the online issue.)
###end p 37
###begin p 38
###xml 277 278 277 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 292 298 292 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 444 450 444 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 461 462 461 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 546 547 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 570 571 570 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
The preceding studies demonstrate that human islets contain cdk-6 but shed no functional light on whether cdk-6 drives cell cycle progression. To study cdk-6 function, we transduced human islets with adenoviruses expressing cdk-4 and cdk-6 alone or in combination with cyclin D1. As shown in Fig. 3A, the transductions were effective with each of the viruses leading to overexpression of the appropriate G1/S control protein. As can be seen in Fig. 3B, cyclin D1 and cdk-6 alone were able to phosphorylate pRb as were the combinations of cyclin D1 plus cdk-4 or cyclin D1 plus cdk-6.
###end p 38
###begin p 39
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 115 117 115 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</italic>
###xml 144 145 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 373 374 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 386 388 386 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</italic>
###xml 444 445 444 445 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 491 492 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 521 522 521 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 215 220 <span type="species:ncbi:9606">human</span>
###xml 265 270 <span type="species:ncbi:9606">human</span>
###xml 405 410 <span type="species:ncbi:9606">human</span>
The effect of overexpression of cdk-4, cdk-6, and cyclin D1 on phosphorylation of the retinoblastoma protein, pRb. A: cdk-4, cdk-6, and cyclin D1 were overexpressed in human islets by their cognate virus but not in human islets transduced with Ad.lacZ or in normal human islets. As assessed using densitometry, cdk-4 was overexpressed 9.8-fold, cdk-6 5.5-fold, and cyclin D1 24.8-fold. B: Transduction of human islets with Ad.cdk-6, Ad.cyclin D1, or combinations of Ad.cdk-4 plus Ad.cyclin D1 or Ad.cdk-6 plus Ad.cyclin D1 leads to phosphorylation of endogenous pRb. This does not occur in the relevant controls or with Ad.cdk-4 alone. In all experiments, 500 MOI was used for 1 h with, for example, 250 MOI of Ad.lacZ plus 250 MOI of Ad.cdk-6 in lanes that contained a single cell cycle activator or 500 MOI of Ad.lacZ in which no cell cycle activator was included. Extracts were prepared and immunoblots performed 3 days after transduction.
###end p 39
###begin p 40
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 196 202 193 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 202 203 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 559 560 550 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 624 625 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 659 665 650 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 665 666 656 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 730 731 721 722 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1043 1049 1016 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 1049 1050 1022 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1199 1200 1172 1173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1242 1243 1215 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1254 1255 1227 1228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1265 1271 1238 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 1271 1272 1244 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
###xml 374 379 <span type="species:ncbi:9606">human</span>
###xml 394 399 <span type="species:ncbi:9606">human</span>
###xml 499 504 <span type="species:ncbi:9606">human</span>
###xml 1420 1423 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
These findings would suggest that the cdk-6/cyclin D1 combination might lead to proliferation of beta-cells. To assess this, human islets were transduced with the combinations of viruses shown in Fig. 4A, and proliferation was assessed in human beta-cells 3 days following transduction. As can be seen in the figure, BrdU-positive cells were rare to absent in nontransduced human islets and in human islets transduced with Ad.lacZ or cdk-4. In contrast, BrdU incorporation was regularly observed in human beta-cells transduced with Ad.cdk-6 alone, Ad.cyclin D1 alone, or combinations of Ad.cdk-4 or Ad.cdk-6 plus Ad.cyclin D1. These results are quantified in Fig. 4B where it can be seen that overexpression of cdk-6 plus cyclin D1 induced a dramatic increase in proliferation with the combination leading to 13% of beta-cells incorporating BrdU as compared with approximately0.3% under basal conditions or after Ad.lacz transduction, an approximate 40-fold increase in proliferation. BrdU incorporation occurs in cells other than beta-cells (Fig. 4A). As shown in supplemental Fig. 2 (available in the online appendix), immunohistochemistry for insulin, glucagon, and somatostatin revealed few BrdU+ cells, suggesting that the remaining BrdU+ noninsulin+ cells in Fig. 4A are likely fibroblasts and endothelial, ductal, residual acinar, and other cell types transduced with Ad.cyclin D1-cdk-6 driven by the generalized CMV promoter.
###end p 40
###begin p 41
###xml 56 57 56 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 59 61 59 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</italic>
###xml 211 212 211 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 214 216 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</italic>
###xml 714 715 708 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 870 871 864 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 885 889 879 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C&#8211;D:</italic>
###xml 957 958 951 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 963 964 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1150 1151 1144 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1163 1164 1157 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 506 511 <span type="species:ncbi:9606">human</span>
###xml 919 924 <span type="species:ncbi:9606">human</span>
Induction of proliferation by cdk-4, cdk-6, and cyclin D1. A: Examples of isolated human islets stained for insulin (green) and BrdU (red) 3 days after transduction with adenoviruses encoding cdk-6 plus cyclin D1. B: Quantification of the BrdU incorporation into beta-cells under each of these conditions. Bars represent SE. "# BrdU/insulin" refers to the number of cells that are positive for BrdU and insulin as a function of the total number of beta-cells counted. "HP samples" refers to the numbers of human pancreatic islet samples examined. "# sections" refers to the number of tissue sections examined. "# fields" refers to the number of high-powered microscope fields examined. LZ, Ad.lacZ; D1, Ad.cyclin D1; C4, Ad.cdk-4; C6, cdk-6. The total MOI used for each experiment was 500, and where combinations were used, for example, "D1," 250 MOI of each Ad.cyclin D1 and Ad.lacZ. C-D: Studies in isolated cultured human islets were similar to those in A and C but were studied 10 days after transduction with BrdU labeling for the final 24 h before harvesting the islets. The colored numbers within the bars indicate the absolute numbers of BrdU+ and insulin+ cells. (A high-quality digital representation of this figure is available in the online issue.)
###end p 41
###begin p 42
###xml 106 112 103 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 112 113 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 195 201 192 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 201 202 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 207 208 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 352 353 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
To determine whether the beta-cell proliferation was sustained for longer than 3 days, the experiments in Fig. 4A were repeated and proliferation assessed 10 days after transduction. As shown in Fig. 4C and D, BrdU incorporation in Ad.lacZ-transduced beta-cells was 1.6% as compared with approximately7% in islets transduced with Ad.cdk-6 plus cyclin D1, indicating that cyclin-cdk-driven proliferation can be sustained for at least 10 days in vitro.
###end p 42
###begin p 43
###xml 225 231 222 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 231 232 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 237 238 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 398 399 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 556 557 550 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 595 601 589 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 601 602 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 607 608 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 92 97 <span type="species:ncbi:9606">human</span>
To determine whether the combinations of cell cycle activators also activated cell death in human beta-cells, we performed propidium iodide staining and examined nuclear pyknosis as a measure of cell death. As can be seen in Fig. 5A and B, cell death represented by nuclear pyknosis was common among beta-cells under basal conditions as well as following cell cycle activation by cdk-6 and cyclin D1, but there were no differences among the groups. These findings were confirmed by measuring cleaved caspace-3 in islets transduced with Ad.cdk-6 and cyclinD1 in the several combinations shown in Fig. 5C and D.
###end p 43
###begin p 44
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 103 109 103 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 111 113 111 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</italic>
###xml 337 339 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</italic>
###xml 464 465 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 487 489 487 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C:</italic>
###xml 586 588 586 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D:</italic>
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
###xml 408 413 <span type="species:ncbi:9606">human</span>
Cell death in human islets transduced with cdk-4, cdk6 and cyclin D1. Abbreviations are the same as in Fig. 4. A: Isolated human islets costained with propidium iodide (red) islets and anti-insulin antisera (green) 3 days after adenoviral transduction. Arrows illustrate pyknotic nuclei that are comparable among the several conditions. B: Quantification of these data. Cell death rates are high in cultured human islets but were not exacerbated by cdk-6, cyclin D1, or the combination. C: An immunoblot for cleaved caspace-3 in the several groups 3 days after adenoviral transduction. D: The densitometric quantification of six such experiments. Bars indicate means +/- SEM. (A high-quality digital representation of this figure is available in the online issue.)
###end p 44
###begin p 45
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 252 258 246 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
To determine whether transduction with cdk-6 plus cyclin D1 might result in dedifferentiation of beta-cells, or loss of beta-cell function, we examined glucose-stimulated insulin secretion studies at days 3 and 10 after transduction. As can be seen in Fig. 6, glucose-stimulated insulin secretion remained robust at both days 3 and 10.
###end p 45
###begin p 46
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 380 386 378 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 56 61 <span type="species:ncbi:9606">human</span>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 286 291 <span type="species:ncbi:9606">human</span>
Glucose-stimulated insulin secretion (GSIS) in isolated human islets transduced with cdk-6 and cyclin D1. GSIS was studied at either 3 days (A) or 10 days (B) after transduction. Five different human islet preparations were used for each panel. Insulin secretion was determined using a human insulin ELISA kit (Alpco). Bars indicate mean +/- SEM. Abbreviations are the same as in Fig. 4.
###end p 46
###begin title 47
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 56 61 <span type="species:ncbi:9606">human</span>
Combined overexpression of cdk-6 and cyclin D1 enhances human islet engraftment, proliferation, and function in vivo.
###end title 47
###begin p 48
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 235 236 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 237 238 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 239 241 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 242 244 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 265 271 262 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 271 272 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 885 886 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1062 1063 1059 1060 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 206 211 <span type="species:ncbi:9606">human</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 509 514 <span type="species:ncbi:9606">human</span>
###xml 659 664 <span type="species:ncbi:9606">human</span>
###xml 987 992 <span type="species:ncbi:9606">human</span>
To determine whether the proliferative effects of cdk-6 and cyclin D1 observed in vitro might translate to enhanced islet engraftment and function in the in vivo setting, we used the marginal mass model of human beta-cell engraftment (6,9,32,33). As can be seen in Fig. 7A, sham-transplanted NOD-SCID mice induced to develop diabetes using streptozotocin remained hyperglycemic in the 450-500 mg/dl range for the 6-week duration of the experiment (negative control). In contrast, mice transplanted with 4,000 human IEQ (positive control) displayed random postprandial blood glucose values in the 150-160 mg/dl range. However, 1,500 nontransduced IEQ or 1,500 human islet IEQ transduced with Ad.LacZ caused only a mild attenuation in hyperglycemia in the 350-400 mg/dl range and therefore constituted an ideal marginal mass. Importantly, 1,500 IEQ transduced with Ad.cdk-6 plus cyclin D1 performed in a fashion far superior to the 1,500 IEQ controls and were indistinguishable from 4,000 human IEQ, indicating an approximate threefold enhancement of cdk-6/cyclinD1-transduced islets over controls. This improvement in blood glucose was sustained for the entire 6 weeks of the study but was reversed by unilateral nephrectomy.
###end p 48
###begin p 49
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 135 137 133 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</italic>
###xml 386 387 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 793 795 783 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</italic>
###xml 1117 1118 1107 1108 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 313 317 <span type="species:ncbi:10090">Mice</span>
###xml 871 875 <span type="species:ncbi:10090">mice</span>
###xml 936 940 <span type="species:ncbi:10090">mice</span>
###xml 960 964 <span type="species:ncbi:10090">mice</span>
###xml 993 998 <span type="species:ncbi:9606">human</span>
###xml 1013 1018 <span type="species:ncbi:9606">human</span>
Cdk-6 and cyclin D1 enhance human islet function in vivo in streptozotocin-induced diabetic NOD-SCID mice. Bars indicate mean +/- SEM. A: Sham-transplanted mice and mice transplanted with 1,500 IEQ alone or 1,500 IEQ transduced with Ad.lacZ are shown in the black lines as described in the key within the figure. Mice transplanted with 1,500 IEQ transduced with Ad.cdk-6 plus Ad.cyclinD1 are shown in green and compared with 4,000 normal, nontransduced IEQ. UNX, unilateral nephrectomy. The numbers in the key refer to the number of experimental animals in each group. The characteristics of the donor islets as provided by the ICRC procurement centers were as follows: average age +/- SEM 42.8 +/- 2.1 years (range 20-66), average viability 88.7% +/- 1.4%, and average purity 77.9% +/- 2.2%. B: Intraperitoneal glucose tolerance testing in normal (nondiabetic) NOD-SCID mice, sham-transplanted streptozotocin-induced diabetic NOD-SCID mice, diabetic NOD-SCID mice transplanted with 4,000 IEQ human islets, 1,500 human IEQ transduced with Ad.lacZ, or 1,500 IEQ transduced with 1,500 IEQ expressing cdk-6 plus cyclin D1. Studies were performed 14-21 days following transplantation. The numbers in parentheses indicate the numbers of animals studied.
###end p 49
###begin p 50
###xml 125 131 125 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 525 526 525 526 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 690 691 690 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
To more rigorously define graft function in vivo, we performed IPGTTs on mice 14-21 days after islet transplant. As shown in Fig. 7B, streptozotocin-induced diabetic NOD-SCID mice treated with sham or with 1,500 IEQ of Ad.lacZ-transduced grafts were markedly glucose intolerant. In contrast, normal NOD-SCID mice displayed excellent glucose tolerance as did streptozotocin-induced diabetic animals transplanted with 4,000 IEQ. Interestingly, diabetic animals transplanted with 1,500 IEQ transduced with Ad.cdk-6 plus cyclin D1 behaved similarly to normal NOD-SCID mice and to diabetic NOD-SCID mice transplanted with 4,000 IEQ. Furthermore, fasting glucose levels in the cdk-6 plus cyclin D1 group were approximately60 mg/dl and comparable with values in nondiabetic NOD-SCID mice and those transplanted with 4,000 IEQ.
###end p 50
###begin p 51
###xml 265 271 262 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Fig. 8</xref>
###xml 271 272 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 277 278 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 371 372 365 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 549 555 540 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Fig. 8</xref>
###xml 555 556 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 701 702 686 687 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 88 93 <span type="species:ncbi:9606">human</span>
To determine whether beta-cell proliferation continued in vivo after transplantation of human islets, we repeated these experiments, this time sacrificing the transplant recipients at 3 days after transplantation after in vivo labeling with BrdU. As can be seen in Fig. 8A and B, BrdU incorporation into beta-cells was abundant and easily observable in the cdk-6/cyclin D1 grafts in vivo. This was in marked contrast to sections from the control grafts in which little or no proliferation was observed in beta-cells. These results are quantified in Fig. 8C, in which nine of 4,829 control graft beta-cells (0.2%) were BrdU-positive as compared with 147 of 3,115 beta-cells (4.7%) in the cdk-6/cyclin D1 group. This difference was highly significant.
###end p 51
###begin p 52
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 82 86 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;B:</italic>
###xml 289 290 280 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 499 501 487 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C:</italic>
###xml 828 829 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 834 836 819 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E:</italic>
###xml 939 946 924 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C. F:</italic>
###xml 983 984 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 989 990 974 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1083 1089 1068 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 1089 1090 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 104 109 <span type="species:ncbi:9606">human</span>
###xml 295 300 <span type="species:ncbi:9606">human</span>
###xml 855 860 <span type="species:ncbi:9606">human</span>
Effects of cdk-6 and cyclin D1 on beta-cell proliferation and cell death in vivo. A-B: Proliferation in human beta-cells in vivo 3 days after transduction and transplantation. BrdU is shown in red and beta-cells are shown in green. Three grafts (three each from Ad.lacZ or Ad.cdk-6/cyclinD1) of human islets were removed by unilateral nephrectomy at day 3 after transduction (day 2 after transplantation) and examined for proliferation. The expanded boxes show examples of BrdU-positive beta-cells. C: Quantification of BrdU-positive insulin-positive cells as a function of total insulin-positive cells. The numbers shown within the bars indicate the number of BrdU-positive (red) beta-cells and of insulin-positive (green) cells. The numbers below the bars indicate the numbers of animals studied with two sections per animal. D and E: TUNEL staining in human islets at 3 days after transplantation. These are the same grafts as shown in A-C. F: Quantification of TUNEL staining in D and E in vivo 3 days after adenoviral transduction and transplantation. Labels are the same as in Fig. 4D. (A high-quality digital representation of this figure is available in the online issue.)
###end p 52
###begin p 53
###xml 178 184 175 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Fig. 8</xref>
###xml 184 185 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 190 191 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 245 251 242 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Fig. 8</xref>
###xml 251 252 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 302 303 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 162 167 <span type="species:ncbi:9606">human</span>
To assess survival of human beta-cells after transduction and engraftment, we examined transferase-mediated dUTP nick-end labeling (TUNEL) staining in these same human grafts in Fig. 8D and E obtained 3 days after engraftment. As can be seen in Fig. 8F, approximately2% of Ad.lacZ and Ad.cdk-6/cyclin D1-transduced beta-cells were TUNEL-positive at day 3 after transplant.
###end p 53
###begin title 54
DISCUSSION
###end title 54
###begin p 55
###xml 73 74 70 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 74 74 71 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4"/>
###xml 74 74 71 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5"/>
###xml 75 76 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 77 78 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 78 78 75 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10"/>
###xml 78 78 75 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11"/>
###xml 78 78 75 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12"/>
###xml 79 81 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 82 84 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 84 84 81 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18"/>
###xml 85 87 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 88 90 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 91 93 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 198 200 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 201 203 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 204 206 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 206 206 200 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30"/>
###xml 207 209 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 309 311 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 312 314 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 315 317 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 295 301 <span type="species:ncbi:10090">murine</span>
###xml 484 489 <span type="species:ncbi:9606">human</span>
###xml 573 578 <span type="species:ncbi:9606">human</span>
###xml 669 674 <span type="species:ncbi:9606">human</span>
Whereas many studies have demonstrated that rodent beta-cells replicate (3-6,9-13,17-19,27,28), most investigators agree that human beta-cell replication either in vitro or in vivo is a rare event (15,17,29-31). We had previously catalogued the molecules that control the G1/S transition in the murine islet (17,23,24). Because of the central role of the G1/S transition in beta-cell cycle control, because of the reported differences in the rates of beta-cell proliferation rates in human versus rodent beta-cells, and in light of the need to develop a means of enhancing human beta-cell regeneration, we analyzed the molecules that control the G1/S checkpoint in the human islet.
###end p 55
###begin p 56
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 574 575 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 680 682 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 795 797 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 28 34 <span type="species:ncbi:10090">murine</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 341 347 <span type="species:ncbi:10090">murine</span>
###xml 388 394 <span type="species:ncbi:10090">murine</span>
###xml 555 561 <span type="species:ncbi:10090">murine</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
###xml 861 867 <span type="species:ncbi:10090">murine</span>
###xml 909 914 <span type="species:ncbi:9606">human</span>
###xml 1005 1010 <span type="species:ncbi:9606">human</span>
We find that in contrast to murine islets which contain little or no cdk-6 (17,23,35,36), each of the four G1/S cyclins and cdks is present in the human islet. In particular, cdk-6, an activator of cell cycle progression in many cell types, is abundant in human islets and specifically within the beta-cell. The inability to detect cdk-6 in murine islets and the central role of cdk-4 in murine islets are supported by the observations that cdk-4 appears to be the downstream mediator of beta-cell proliferation induced by the IRS-1-PI3 kinase pathway in murine beta-cells (8) that knockout of cdk-4 leads to severe beta-cell attrition and neonatal diabetic ketoacidosis in mice (21), whereas cdk-6 knockout mice display no beta-cell phenotype but instead have severe hematologic abnormalities (36). Our observations suggest that although cdk-4 is essential to murine islet development and function, cdk-4 in human islets is likely redundant with cdk-6, which may play a similar and complimentary role in human beta-cells.
###end p 56
###begin p 57
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 221 222 218 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 301 303 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 485 486 479 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 715 717 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 720 726 708 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 726 727 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 853 854 838 839 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 930 931 915 916 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 945 947 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1020 1021 1002 1003 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1174 1175 1156 1157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 226 231 <span type="species:ncbi:9606">human</span>
###xml 530 535 <span type="species:ncbi:9606">human</span>
###xml 982 987 <span type="species:ncbi:9606">human</span>
In functional terms, overexpression of cdk-6 in combination with cyclin D1 leads to uniquely robust proliferation in human beta-cells. We have previously demonstrated that cdk-4 overexpression in combination with cyclin D1 in human beta-cells led to an approximate ninefold increase in proliferation (23). However, these studies were limited entirely to in vitro observations for 48-72 h. We report that a second combination of cell cycle activators (cdk-6 in combination with cyclin D1) can induce an even greater stimulation in human beta-cell replication-for some, 40-fold. Furthermore, unlike cdk-4 overexpression, which alone is unable to either measurably phosphorylate pRb or activate beta-cell replication (23) (Fig. 3B), cdk-6 overexpression alone is able to accomplish both of these outcomes, presumably by combining with endogenous beta-cell d-type cyclins. Furthermore, as we previously reported for the cdk-4/cyclin D1 combination (23), cell death was not activated in human beta-cells by the cdk-6/cyclin D1 combination. Future studies will be required to define whether cdk-6 alone will prove as effective in vivo as when supplied in combination with cyclin D1.
###end p 57
###begin p 58
###xml 197 199 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 200 202 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 203 205 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 205 205 202 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30"/>
###xml 206 208 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 775 777 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 802 804 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 823 825 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 839 841 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 937 938 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 938 938 929 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10"/>
###xml 938 938 929 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11"/>
###xml 938 938 929 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12"/>
###xml 939 941 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 331 336 <span type="species:ncbi:9606">human</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
###xml 563 568 <span type="species:ncbi:9606">human</span>
###xml 600 605 <span type="species:ncbi:9606">human</span>
###xml 713 718 <span type="species:ncbi:9606">human</span>
###xml 969 974 <span type="species:ncbi:9606">human</span>
Perhaps the most critical observation in the current study is that, unlike prior in vitro studies with human islets and human autopsy specimens in which human beta-cell replication does not occur (15,17,29-31), induction of human beta-cell replication can be documented and quantified in vivo for the first time using the NOD-SCID human islet transplant model described here. In addition, the whole-animal glucose and insulin metabolic axis can simultaneously be monitored. Although the diabetic NOD-SCID mouse model is not novel, its use to document accelerated human beta-cell replication is. This human islet transplant model is important, because it will permit investigators to ask for the first time, using human islets, whether interventions such as glucose infusion (37), diet-induced obesity (20), lipid infusion (38), pregnancy (27), or treatment with growth factors or drugs such as GLP-1, exenatide, gastrin, EGF, or others (9-13) can lead to activation of human beta-cell replication in vivo.
###end p 58
###begin p 59
###xml 754 756 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 756 756 753 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20"/>
###xml 756 756 753 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21"/>
###xml 756 756 753 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22"/>
###xml 756 756 753 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23"/>
###xml 756 756 753 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24"/>
###xml 756 756 753 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25"/>
###xml 757 759 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 160 166 <span type="species:ncbi:10090">murine</span>
###xml 379 384 <span type="species:ncbi:9606">human</span>
###xml 704 709 <span type="species:ncbi:9606">human</span>
###xml 733 739 <span type="species:ncbi:10090">murine</span>
In addition to the studies centered on cdk-6, the human G1/S proteome reveals a variety of additional novel observations. For example, human islets, like their murine counterparts, contain all seven INK4 and CIP/KIP/WAF family members, all three pocket proteins, menin, and p53. That is, every single cell cycle inhibitor that might be present in any cell type is present in the human islet; if one wanted to design a cell type that could not possibly replicate, this is how it would be accomplished. Their simple presence of course does not prove function, but this model will also allow further detailed in vivo study. For example, physiological and therapeutic activation of cell cycle progression in human beta-cells, like their murine counterparts (19-26), might be accomplished by knockdown or silencing of individual or combinations of cell cycle inhibitors such as menin, p18 and p27, or pRb and p53.
###end p 59
###begin p 60
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 246 252 <span type="species:ncbi:10090">murine</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 442 448 <span type="species:ncbi:10090">murine</span>
Another novel observation is that human islets contain all three pocket protein members, pRb, p107, and p130; previously, only pRb has been identified in human islets (23). As another example, human islets lack E2F2, a protein that is present in murine islets (17,23,24) and the loss of which in knockout mice leads to severe pancreatic exocrine and endocrine dysfunction (39,40). Similarly, human islets contain E2F3 and E2F7, whereas their murine counterparts lack both E2F3 and E2F7 (17,23,24). The functional and therapeutic implications of these observations are currently unknown but clearly merit further exploration.
###end p 60
###begin p 61
###xml 376 377 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 378 380 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 381 383 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 505 507 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
A number of additional important questions remain for future studies. One important question relates to the quantification of beta-cell mass loss or accrual in this model. It would be ideal to be able to accurately assess beta-cell mass as well as beta-cell differentiation. However, this will be challenging given the complex mixture of cell types contained in islet grafts (6,32,41). Potential approaches to quantitate increments in beta-cell mass might include intraocular anterior chamber transplant (42) or combining insulin promoter-driven viral delivery of luciferase with external imaging coupled with graft histomorphometry.
###end p 61
###begin p 62
###xml 70 75 <span type="species:ncbi:9606">human</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 432 437 <span type="species:ncbi:9606">human</span>
It is also important to emphasize that the immunoblots describing the human G1/S proteome were performed on whole human islets, which are comprised predominantly of non-beta-cells. Thus, for the cell cycle proteins described (other than cdk-4 and cdk-6, which were confirmed to be present in the beta-cell using immunohistochemistry), future studies will need to unequivocally document the presence or absence of these molecules in human beta-cells.
###end p 62
###begin p 63
###xml 131 132 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 498 500 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
Another important question relates to the duration of the adenovirus expression and beta-cell replication induced by cdk-6/cyclin D1. We have examined only a single early time point, but it is important to know whether adenoviral expression is sustained for the entire 6 weeks of the experiment or even longer. In this regard, we have recently demonstrated, using a similar model, that adenoviral expression of hepatocyte growth factor in transplanted primate islets persists for at least 6 weeks (43).
###end p 63
###begin p 64
###xml 1136 1137 1118 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 145 150 <span type="species:ncbi:9606">human</span>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 888 893 <span type="species:ncbi:9606">human</span>
###xml 1089 1094 <span type="species:ncbi:9606">human</span>
###xml 1122 1128 <span type="species:ncbi:10090">murine</span>
Although we show that cdk-6 overexpression is able to activate the beta-cell cycle, this does not address the physiological role of cdk-6 in the human beta-cell nor mechanisms through which it acts. Further studies will be required to define the consequences of cdk-6 loss on human beta-cells and to identify the cyclin INK/KIP/CIP partners of cdk-6. This is particularly interesting in that the large majority of cdk-6 is present in the cytosolic compartment, not the nuclear compartment where it might phosphorylate pocket proteins. Is cdk-6 a cytosolic protein only in resting beta-cells that translocates to the nucleus in proliferating beta-cells? Or does cdk-6 always remain in the cytoplasm? Can it drive cell cycle progression by sequestering CIPs/KIPs in the cytoplasm away from cdk-1/cdk-2 cyclin A/E complexes? Answering these questions and others will require purification of human beta-cells, coimmunoprecipitaton, colocalization, live-cell imaging, and other studies. In addition, whether cdk-6 expression or activity is regulated by growth factors and signaling pathways in human islets, as is cdk-4 in the murine islet (8), provides fertile ground for future study.
###end p 64
###begin p 65
###xml 282 283 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 334 334 334 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45"/>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
Finally, cdks and cyclins are oncogenes. This raises the question as to whether sustained therapeutic cdk or cyclin activation might have oncogenic consequences. On the "high oncogenic risk" side of the equation, cdk-4 is associated with melanoma and other malignancies and cyclin D1 with insulinomas, breast cancer, and lymphomas (44-46). On the "low oncogenic risk" side of the equation, these cell cycle molecules of course are also normal regulators of cell cycle replication in all cells, including beta-cells. Under normal physiological circumstances, their level of expression is tightly controlled and does not lead to tumor development but suffices to expand beta-cell mass in embryology and childhood. Thus, if it were possible to control the duration and degree of expression of these molecules through the use of beta-cell-specific and regulatable promoters, their degree and duration of activation might be engineered to mimic physiological beta-cell replication and expansion. Because the islet grafts can be left in place for months or even 1 or 2 years, the model described here will permit accurate and meaningful study of their oncogenicity.
###end p 65
###begin p 66
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 325 330 <span type="species:ncbi:9606">human</span>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 578 583 <span type="species:ncbi:9606">human</span>
###xml 630 635 <span type="species:ncbi:9606">human</span>
###xml 671 676 <span type="species:ncbi:9606">human</span>
###xml 728 733 <span type="species:ncbi:9606">human</span>
###xml 959 964 <span type="species:ncbi:9606">human</span>
###xml 1151 1156 <span type="species:ncbi:9606">human</span>
###xml 1212 1217 <span type="species:ncbi:9606">human</span>
In summary, we have provided a human beta-cell cycle "G1/S proteome," which can serve as a road map or model to more deeply understand and exploit human beta-cell replication. We have also developed an in vivo model in which to explore the function of these molecules as well as a broad variety of physiological maneuvers on human beta-cell replication. We have also demonstrated a variety of other unanticipated differences between rodent and human G1/S regulatory machinery. Collectively, these studies make three fundamental points. First, rodent studies aimed at augmenting human beta-cell replication need to be confirmed in human islets; if one wants to understand human beta-cell replication, one will need also to study human beta-cells. Second, although progress is being made in understanding the molecular details of cell cycle control in the pancreatic beta-cell, current understanding is still rudimentary. Third, it is clearly possible to drive human beta-cell replication in ways that retain differentiation and function in vivo, at least over a period of days to weeks. Approaches designed to exploit fundamental cell cycle control in human beta-cells may provide insight into how best to expand human beta-cells for therapeutic purposes in the treatment of diabetes.
###end p 66
###begin title 67
Supplementary Material
###end title 67
###begin title 68
Online-Only Appendix
###end title 68
###begin p 69
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 69
###begin title 70
Acknowledgments
###end title 70
###begin p 71
This research was supported by National Institutes of Health Grants R-01 DK5502 and T-32 DK07052, American Diabetes Association Grant 1-06-134, and Juvenile Diabetes Research Foundation (JDRF) Grant 1-2008-39.
###end p 71
###begin p 72
No potential conflicts of interest relevant to this article were reported.
###end p 72
###begin p 73
We thank the NIDDK- and JDRF-supported Islet Cell Resource Center for providing the majority of the islets used in these studies. We thank the Don and Arleen Wagner and the Kroh Family Foundations for supporting these studies. We thank Dr. Simon Watkins at the University of Pittsburgh Center for Biological Imaging for help with confocal microscopy and Bennet Smith for technical help. We also thank Dr. Alan Attie and Jeremy Lavine at the University of Wisconsin for helpful advice and comments.
###end p 73
###begin title 74
REFERENCES
###end title 74
###begin article-title 75
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. 
###end article-title 75
###begin article-title 76
Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. 
###end article-title 76
###begin article-title 77
Adult pancreatic ss-cells are formed by self-duplication rather than stem-cell differentiation. 
###end article-title 77
###begin article-title 78
All beta cells contribute equally to islet growth and maintenance. 
###end article-title 78
###begin article-title 79
###xml 26 30 <span type="species:ncbi:10090">mice</span>
Recovery from diabetes in mice by beta cell regeneration. 
###end article-title 79
###begin article-title 80
Protein kinase C-zeta activation markedly enhances beta cell proliferation. 
###end article-title 80
###begin article-title 81
Calcineurin/NFAT signaling regulates pancreatic ss-cell growth and function. 
###end article-title 81
###begin article-title 82
Akt induces beta-cell proliferation by regulating cyclin d1, cyclin d2, and p21 levels and cyclin-dependent kinase-4 activity. 
###end article-title 82
###begin article-title 83
###xml 57 63 <span type="species:ncbi:10090">murine</span>
Adenovirus-mediated hepatocyte growth factor transfer to murine islets improves pancreatic islet transplant performance and reduces beta cell death. 
###end article-title 83
###begin article-title 84
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Combination therapy with epidermal growth factor and gastrin increases beta cell mass and reverses hyperglycemia in diabetic NOD mice. 
###end article-title 84
###begin article-title 85
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. 
###end article-title 85
###begin article-title 86
###xml 91 95 <span type="species:ncbi:10090">mice</span>
NeuroD-betacellulin therapy induces islet neogenesis in the liver and reverses diabetes in mice. 
###end article-title 86
###begin article-title 87
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 87 93 <span type="species:ncbi:10090">murine</span>
Characterization of mice doubly transgenic for parathyroid hormone-related protein and murine placental lactogen: a novel role for placental lactogen in pancreatic beta cell survival. 
###end article-title 87
###begin article-title 88
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?
###end article-title 88
###begin article-title 89
###xml 55 61 <span type="species:ncbi:9606">humans</span>
Beta cell deficit and increased beta cell apoptosis in humans with diabetes. 
###end article-title 89
###begin article-title 90
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Selective ss cell loss and alpha cell expansion in patients with type 2 diabetes mellitus in Korea. 
###end article-title 90
###begin article-title 91
Molecular control of cell cycle progression in the pancreatic beta cell. 
###end article-title 91
###begin article-title 92
Intrinsic regulators of pancreatic beta-cell proliferation. 
###end article-title 92
###begin article-title 93
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27kip1 and p18Ink4c. 
###end article-title 93
###begin article-title 94
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cdkn1b</italic>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Deletion of cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. 
###end article-title 94
###begin article-title 95
Loss of expression of cdk4 causes insulin-deficient diabetes and cdk4 activation results in beta cell hyperplasia. 
###end article-title 95
###begin article-title 96
Essential role of skp-2-mediated p27 degradation in growth and adaptive expansion of pancreatic beta cells. 
###end article-title 96
###begin article-title 97
###xml 171 172 171 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 83 86 <span type="species:ncbi:10116">rat</span>
###xml 91 96 <span type="species:ncbi:9606">human</span>
Induction of beta cell proliferation and retinoblastoma protein phosphorylation in rat and human islets using adenoviral delivery of cyclin-dependent kinase-4 and cyclin D1. 
###end article-title 97
###begin article-title 98
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip</sup>
The cell cycle inhibitory protein, p21cip, is not essential for maintaining beta cell cycle arrest or beta cell function in vivo. 
###end article-title 98
###begin article-title 99
Tissue-specific deletion of the retinoblastoma protein in the pancreatic beta cell has limited effects on beta cell replication, mass and function. 
###end article-title 99
###begin article-title 100
p16ink4a induces an age-dependent decline in islet regenerative potential. 
###end article-title 100
###begin article-title 101
Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. 
###end article-title 101
###begin article-title 102
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. 
###end article-title 102
###begin article-title 103
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human pancreatic beta cell deoxyribonucleic acid synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. 
###end article-title 103
###begin article-title 104
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 34 37 <span type="species:ncbi:10116">rat</span>
Proliferation of sorted human and rat beta cells. 
###end article-title 104
###begin article-title 105
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 82 91 <span type="species:ncbi:10090">nude mice</span>
A selective decrease in beta cell mass of human islets transplanted into diabetic nude mice. 
###end article-title 105
###begin article-title 106
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Gene transfer of constitutively active Akt markedly improves human islet transplant outcomes in diabetic severe combined immunodeficient mice. 
###end article-title 106
###begin article-title 107
###xml 139 142 <span type="species:ncbi:10116">rat</span>
Hepatocyte growth factor gene therapy for pancreatic islets: reducing the minimal requisite islet transplant mass in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. 
###end article-title 107
###begin article-title 108
###xml 83 88 <span type="species:ncbi:9606">human</span>
###xml 93 99 <span type="species:ncbi:10090">murine</span>
###xml 128 133 <span type="species:ncbi:9606">human</span>
Comprehensive comparative cell cycle analysis reveals critical differences between human and murine beta cell cycle regulation: human islets contain Cdk-6 but lack Cdk-4. In 
###end article-title 108
###begin article-title 109
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Genetic rescue of cdk-4-null mice restores pancreatic beta cell proliferation but not homeostatic cell number. 
###end article-title 109
###begin article-title 110
Mammalian cell cycle without D-type cyclin-dependent kinases cdk-4 and cdk-6. 
###end article-title 110
###begin article-title 111
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Glucose infusion in mice: a new model to induce beta-cell replication. 
###end article-title 111
###begin article-title 112
###xml 64 68 <span type="species:ncbi:10116">rats</span>
Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and pdx-1 binding in islets. 
###end article-title 112
###begin article-title 113
###xml 48 52 <span type="species:ncbi:10090">mice</span>
The development of diabetes in E2F1/E2F2 mutant mice reveals important roles for bone marrow derived cells in preventing islet loss. 
###end article-title 113
###begin article-title 114
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double mutant mice. 
###end article-title 114
###begin article-title 115
###xml 32 37 <span type="species:ncbi:9606">human</span>
Experimental transplantation of human fetal and adult pancreatic islets. 
###end article-title 115
###begin article-title 116
Non-invasic imaging of pancreatic islet cell biology. 
###end article-title 116
###begin article-title 117
###xml 72 77 <span type="species:ncbi:9606">human</span>
Hepatocyte growth factor (HGF) enhances engraftment and function of non-human primate islets. 
###end article-title 117
###begin article-title 118
###xml 49 54 <span type="species:ncbi:9606">human</span>
Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. 
###end article-title 118
###begin article-title 119
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Wide spectrum of tumors in knock-in mice carrying a cdk4 protein insensitive to INK4 inhibitors. 
###end article-title 119
###begin article-title 120
Oncogenes and cancer. 
###end article-title 120

